Hypertrophic obstructive cardiomyopathy (HOCM) is a common inheritable cardiac disorder that can lead to symptoms of dyspnea, angina pectoris, and syncope. Symptomatic patients are usually treated with negatively inotropic agents, such as beta-blockers, calcium channel blockers, or disopyramide. However, up to 10% of patients with outflow pressure gradient are unresponsive to medical therapy. Until the early 1990s, surgical myectomy represented the standard treatment for patients with HOCM and drug-refractory symptoms. More than one decade ago, alcohol septal ablation (ASA) was introduced as a less invasive alternative therapy for symptomatic HCM patients with obstruction. ASA is performed through a percutaneous approach, in which 1-3 ml of absolute alcohol is introduced into the septal branch to create a controlled septal infarction of the basal interventricular septum. This procedure results in relief of symptoms, a decrease in the pressure gradient, and improvement in left ventricular diastolic function. A randomized controlled trial is needed to compare ASA and surgical myectomy in order to determine which technique provides maximal benefit.

Cardiovascular Center University Hospital Motol Prague Czech Republic

Ten Tips and Tricks for Performing Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy

Long-term outcome of repeated septal reduction therapy after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: insight from the Euro-ASA registry

Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background

How to Treat Obstructions in Patients with Hypertrophic Cardiomyopathy

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective